CY1118664T1 - Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου - Google Patents

Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου

Info

Publication number
CY1118664T1
CY1118664T1 CY20171100260T CY171100260T CY1118664T1 CY 1118664 T1 CY1118664 T1 CY 1118664T1 CY 20171100260 T CY20171100260 T CY 20171100260T CY 171100260 T CY171100260 T CY 171100260T CY 1118664 T1 CY1118664 T1 CY 1118664T1
Authority
CY
Cyprus
Prior art keywords
toxin
difficile
toy
proteins
tab
Prior art date
Application number
CY20171100260T
Other languages
English (en)
Inventor
Larry Ellingsworth
David Flyer
Jing-Hui Tian
Steven Fuhrmann
Stefanie Kluepfel-Stahl
Gregory Glenn
Kerstin Westritschnig
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44799993&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118664(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of CY1118664T1 publication Critical patent/CY1118664T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει απομονωμένα πολυπεπτίδια C-TAB.G5 και C-TAB.G5.1 που περιέχουν τις περιοχές δέσμευσης υποδοχέα τοξίνης Α και τοξίνης Β του C. difficile όπως παρατίθενται στις αλληλουχίες αμινοξέων της SEQ ID NO: 2 και SEQ ID NO: 4. Τα απομονωμένα πολυπεπτίδια C-TAB.G5 και C-TAB.G5.1 μπορούν να χρησιμοποιηθούν σε εξουδετέρωση των τοξικών επενεργειών τοξίνης Α και/ή τοξίνης Β του C. difficile.
CY20171100260T 2010-09-03 2017-02-24 Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου CY1118664T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37989210P 2010-09-03 2010-09-03
PCT/EP2011/065304 WO2012028741A1 (en) 2010-09-03 2011-09-05 Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Publications (1)

Publication Number Publication Date
CY1118664T1 true CY1118664T1 (el) 2017-07-12

Family

ID=44799993

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100260T CY1118664T1 (el) 2010-09-03 2017-02-24 Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου

Country Status (22)

Country Link
US (6) US9598472B2 (el)
EP (3) EP3167899B1 (el)
JP (1) JP6121421B2 (el)
KR (1) KR101907434B1 (el)
CN (1) CN103957931B (el)
AU (1) AU2011298306B2 (el)
BR (1) BR112014004896B1 (el)
CA (1) CA2873272C (el)
CY (1) CY1118664T1 (el)
DK (1) DK2753352T4 (el)
ES (2) ES2867375T3 (el)
HK (1) HK1200357A1 (el)
HR (1) HRP20170193T4 (el)
HU (1) HUE033342T2 (el)
LT (1) LT2753352T (el)
MX (1) MX350126B (el)
PL (1) PL2753352T5 (el)
PT (1) PT2753352T (el)
RS (1) RS55707B2 (el)
SI (1) SI2753352T2 (el)
WO (1) WO2012028741A1 (el)
ZA (1) ZA201400610B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2753352T (lt) 2010-09-03 2017-05-25 Valneva Austria Gmbh Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
NZ616035A (en) 2011-04-22 2016-03-31 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
EP2714911B1 (en) 2011-05-27 2016-11-30 GlaxoSmithKline Biologicals S.A. Immunogenic composition
AU2016203241B2 (en) * 2011-05-27 2018-05-10 Glaxosmithkline Biologicals S.A. Immunogenic composition
JP6084631B2 (ja) 2011-12-08 2017-02-22 ノバルティス アーゲー Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2014086787A1 (en) * 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
GB2525177A (en) * 2014-04-14 2015-10-21 New Royal Holloway & Bedford Vaccine
WO2016131157A1 (en) * 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
CA3014498A1 (en) * 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
JP7426953B2 (ja) 2018-06-19 2024-02-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
US20220144924A1 (en) * 2019-02-25 2022-05-12 Previpharma Consulting Gmbh Epitopes of clostridium difficile toxins a and b and uses thereof
CA3174599A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improvements in vaccine formulations for medical use
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5736139A (en) 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
ATE366312T1 (de) * 1994-10-24 2007-07-15 Ophidian Pharm Inc Impfstoff und antitoxine zur behandlung und vorbeugung von c. difficile krankheiten
NZ312502A (en) 1995-07-07 1999-03-29 Oravax Inc Clostridium difficile toxins as mucosal adjuvants
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
WO1998014202A1 (en) 1996-10-04 1998-04-09 Auckland Uniservices Limited Regulation of neural enzymes
EP0952850A2 (en) 1996-12-31 1999-11-03 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
EP1169456B1 (en) 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AU2001289813B2 (en) 2000-08-17 2005-07-28 Intercell Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
EP1390494A2 (en) 2001-05-21 2004-02-25 Intercell AG Method for stabilising of nucleic acids
CA2452909A1 (en) 2001-12-07 2003-06-13 Intercell Ag Immunostimulatory oligodeoxynucleotides
CA2553946C (en) * 2004-02-06 2019-02-26 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
ATE495747T1 (de) 2004-08-23 2011-02-15 Teva Pharma Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
CN101500581B (zh) * 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
AU2008263591C1 (en) * 2007-06-14 2013-09-26 The Secretary Of State For Health Chemically modified peptides with improved immunogenicity
CA2699435A1 (en) 2007-09-14 2009-03-19 Sanofi Pasteur Biologics Co. Pharmaceutical compositions containing clostridium difficile toxoids a and b
EP2318515A4 (en) * 2008-08-06 2012-11-14 Emergent Product Dev Uk Ltd DIFFICULT CLOSTRIDIUM VACCINES, AND METHODS OF USE
WO2011060431A2 (en) † 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
AU2011239470B2 (en) 2010-04-15 2015-09-10 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
LT2753352T (lt) 2010-09-03 2017-05-25 Valneva Austria Gmbh Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
NZ616035A (en) * 2011-04-22 2016-03-31 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
EP2714911B1 (en) 2011-05-27 2016-11-30 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB201206070D0 (en) * 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
WO2014086787A1 (en) * 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
US9181632B1 (en) * 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof

Also Published As

Publication number Publication date
CN103957931A (zh) 2014-07-30
US10821166B2 (en) 2020-11-03
BR112014004896A2 (pt) 2021-01-26
DK2753352T4 (da) 2022-09-12
ES2631032T5 (es) 2022-10-26
US20210121554A1 (en) 2021-04-29
HRP20170193T1 (hr) 2017-06-02
EP3895728A1 (en) 2021-10-20
MX2014002595A (es) 2014-10-13
CA2873272C (en) 2020-10-27
US20230173052A1 (en) 2023-06-08
EP3167899A1 (en) 2017-05-17
JP6121421B2 (ja) 2017-04-26
PT2753352T (pt) 2017-03-08
MX350126B (es) 2017-08-28
HUE033342T2 (en) 2017-11-28
PL2753352T3 (pl) 2017-07-31
ES2631032T3 (es) 2017-08-25
HRP20170193T4 (hr) 2022-09-02
DK2753352T5 (da) 2017-05-01
PL2753352T5 (pl) 2022-10-17
BR112014004896B1 (pt) 2023-02-14
US20190290747A1 (en) 2019-09-26
US10357557B2 (en) 2019-07-23
US20210393761A1 (en) 2021-12-23
JP2014525249A (ja) 2014-09-29
US20150056238A1 (en) 2015-02-26
ZA201400610B (en) 2015-09-30
LT2753352T (lt) 2017-05-25
EP2753352A1 (en) 2014-07-16
AU2011298306B2 (en) 2017-10-19
SI2753352T1 (sl) 2017-06-30
KR101907434B1 (ko) 2018-10-12
KR20140057315A (ko) 2014-05-12
EP2753352B1 (en) 2017-01-25
WO2012028741A1 (en) 2012-03-08
US11478540B2 (en) 2022-10-25
AU2011298306A1 (en) 2014-02-20
HK1200357A1 (en) 2015-08-07
DK2753352T3 (da) 2017-03-06
US20170239340A1 (en) 2017-08-24
SI2753352T2 (sl) 2022-10-28
CN103957931B (zh) 2017-10-24
EP3167899B1 (en) 2021-03-24
EP2753352B2 (en) 2022-08-10
ES2867375T3 (es) 2021-10-20
CA2873272A1 (en) 2012-03-08
RS55707B1 (sr) 2017-07-31
US11357844B2 (en) 2022-06-14
US9598472B2 (en) 2017-03-21
RS55707B2 (sr) 2022-10-31

Similar Documents

Publication Publication Date Title
CY1118664T1 (el) Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
RS53505B1 (en) OXYTOMODULIN PEPTIDE ANALOG
MX360741B (es) Constructos de polipéptidos y sus usos.
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
MX2014011459A (es) Proteinas nutritivas cargadas y metodos.
NZ628446A (en) Fibronectin based scaffold domain proteins that bind to myostatin
IN2014KN01713A (el)
NZ600732A (en) Oxyntomodulin peptide analogue
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
IN2014KN01716A (el)
IN2014KN01714A (el)
MX2011011132A (es) Peptido auxiliar del antigeno del cancer.
AR086199A1 (es) Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
NZ703560A (en) Method for activating helper t cell
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
NZ706884A (en) Fc gamma receptor iib variants
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy